the PD-1/PD-L1 pathway have a limited impact because they do not produce the synergistic inhibitory effects on VEGF-A or WNT/β-catenin mutation that are obtained with combination therapy using an ICI plus an anti-VEGF antibody or TKIs.
No takes yet. Share an insight, caveat, or question.
Masatoshi Kudo (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: